Citigroup’s AnaptysBio ANAB Stock Holding History

Citigroup’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45,000	Closed	-$596K	–	5549
2024 Q4	$596K	Buy	+45,000	New	+$1.09M	﹤0.01%	3707
2024 Q3	–	Sell	-24,000	Closed	-$601K	–	5667
2024 Q2	$601K	Sell	24,000 -6,000	-20%	-$140K	﹤0.01%	3271
2024 Q1	$676K	Hold	30,000	–	–	﹤0.01%	3342
2023 Q4	$643K	Hold	30,000	–	–	﹤0.01%	3214
2023 Q3	$539K	Hold	30,000	–	–	﹤0.01%	3001
2023 Q2	$610K	Buy	+30,000	New	+$608K	﹤0.01%	3231
2020 Q2	–	Sell	-2,500	Closed	-$35K	–	7522
2020 Q1	$35K	Sell	2,500 -10,900	-81%	-$165K	﹤0.01%	6284
2019 Q4	$218K	Sell	13,400 -6,100	-31%	-$144K	﹤0.01%	5112
2019 Q3	$682K	Buy	19,500 +3,500	+22%	+$167K	﹤0.01%	4043
2019 Q2	$903K	Buy	16,000 +15,200	+1,900%	+$1.09M	﹤0.01%	3750
2019 Q1	$58K	Sell	800 -2,200	-73%	-$152K	﹤0.01%	6205
2018 Q4	$191K	Buy	3,000 +500	+20%	+$37.2K	﹤0.01%	5062
2018 Q3	$249K	Buy	+2,500	New	+$207K	﹤0.01%	5012

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citigroup's ANAB Position: Q1 2026 in Review

Citigroup reduced its AnaptysBio (ANAB) stake by 0.06% in Q1 2026, selling an estimated $2.53K and leaving 73,406 shares worth $4.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2123.

Citigroup first reported a position in ANAB in Q1 2017 and has held it in 37 quarters since. The position peaked at $23.2M in Q2 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

Citigroup held 73,406 shares of AnaptysBio worth $4.07M as of Q1 2026.
Citigroup sold 47 AnaptysBio shares in Q1 2026, an estimated $2.53K.
AnaptysBio made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2123 holding.
Citigroup first reported a position in AnaptysBio in Q1 2017 and has held it in 37 quarters since.
Citigroup's AnaptysBio position peaked at $23.2M in Q2 2025.
207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.